S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:ESTA

Establishment Labs Competitors

$69.03
+1.68 (+2.49 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$65.30
Now: $69.03
$69.73
50-Day Range
$37.91
MA: $56.33
$73.76
52-Week Range
$7.56
Now: $69.03
$76.91
Volume84,534 shs
Average Volume104,806 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15

Competitors

Establishment Labs (NASDAQ:ESTA) Vs. MSA, EAR, AVNS, INGN, SIEN, and IVC

Should you be buying ESTA stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Establishment Labs, including MSA Safety (MSA), Eargo (EAR), Avanos Medical (AVNS), Inogen (INGN), Sientra (SIEN), and Invacare (IVC).

Establishment Labs (NASDAQ:ESTA) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Establishment Labs and MSA Safety, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01402.80
MSA Safety01202.67

Establishment Labs currently has a consensus target price of $41.40, suggesting a potential downside of 40.03%. MSA Safety has a consensus target price of $138.6667, suggesting a potential downside of 13.87%. Given MSA Safety's higher probable upside, analysts plainly believe MSA Safety is more favorable than Establishment Labs.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 77.2% of MSA Safety shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 7.0% of MSA Safety shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Establishment Labs and MSA Safety's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11
MSA Safety$1.40 billion4.49$136.44 million$4.8033.54

MSA Safety has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than MSA Safety, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Establishment Labs and MSA Safety's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
MSA Safety10.40%23.96%10.13%

Risk and Volatility

Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Summary

MSA Safety beats Establishment Labs on 10 of the 14 factors compared between the two stocks.

Eargo (NASDAQ:EAR) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Eargo and Establishment Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eargo00403.00
Establishment Labs01402.80

Eargo currently has a consensus price target of $48.00, suggesting a potential downside of 17.82%. Establishment Labs has a consensus price target of $41.40, suggesting a potential downside of 40.03%. Given Eargo's stronger consensus rating and higher probable upside, analysts plainly believe Eargo is more favorable than Establishment Labs.

Profitability

This table compares Eargo and Establishment Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EargoN/AN/AN/A
Establishment Labs-46.40%-49.51%-24.21%

Valuation & Earnings

This table compares Eargo and Establishment Labs' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EargoN/AN/AN/AN/AN/A
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11

Eargo has higher earnings, but lower revenue than Establishment Labs.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Eargo beats Establishment Labs on 5 of the 8 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Avanos Medical has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Avanos Medical and Establishment Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avanos Medical$697.60 million3.15$-45,900,000.00$1.0742.97
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11

Establishment Labs has lower revenue, but higher earnings than Avanos Medical. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avanos Medical and Establishment Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avanos Medical1.93%3.20%2.28%
Establishment Labs-46.40%-49.51%-24.21%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Avanos Medical and Establishment Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avanos Medical12202.20
Establishment Labs01402.80

Avanos Medical currently has a consensus target price of $38.40, suggesting a potential downside of 16.49%. Establishment Labs has a consensus target price of $41.40, suggesting a potential downside of 40.03%. Given Avanos Medical's higher possible upside, research analysts clearly believe Avanos Medical is more favorable than Establishment Labs.

Institutional and Insider Ownership

94.8% of Avanos Medical shares are held by institutional investors. Comparatively, 54.8% of Establishment Labs shares are held by institutional investors. 1.5% of Avanos Medical shares are held by insiders. Comparatively, 2.6% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Avanos Medical beats Establishment Labs on 8 of the 14 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Volatility & Risk

Establishment Labs has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings and Valuation

This table compares Establishment Labs and Inogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11
Inogen$361.94 million3.21$20.95 million$1.0749.06

Inogen has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Establishment Labs and Inogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
Inogen-0.66%0.21%0.16%

Analyst Ratings

This is a summary of recent ratings and target prices for Establishment Labs and Inogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01402.80
Inogen03102.25

Establishment Labs presently has a consensus price target of $41.40, indicating a potential downside of 40.03%. Inogen has a consensus price target of $63.00, indicating a potential upside of 20.02%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Establishment Labs.

Summary

Inogen beats Establishment Labs on 9 of the 14 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Establishment Labs and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01402.80
Sientra00603.00

Establishment Labs presently has a consensus price target of $41.40, suggesting a potential downside of 40.03%. Sientra has a consensus price target of $8.20, suggesting a potential upside of 5.40%. Given Sientra's stronger consensus rating and higher probable upside, analysts plainly believe Sientra is more favorable than Establishment Labs.

Volatility & Risk

Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

Profitability

This table compares Establishment Labs and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
Sientra-123.88%-174.05%-38.97%

Earnings & Valuation

This table compares Establishment Labs and Sientra's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11
Sientra$83.70 million4.69$-106,820,000.00($2.29)-3.40

Establishment Labs has higher revenue and earnings than Sientra. Establishment Labs is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.8% of Establishment Labs shares are held by institutional investors. Comparatively, 71.0% of Sientra shares are held by institutional investors. 2.6% of Establishment Labs shares are held by insiders. Comparatively, 2.8% of Sientra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Establishment Labs (NASDAQ:ESTA) and Invacare (NYSE:IVC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Profitability

This table compares Establishment Labs and Invacare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
Invacare-4.87%-8.76%-3.07%

Analyst Ratings

This is a breakdown of current ratings for Establishment Labs and Invacare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01402.80
Invacare00203.00

Establishment Labs currently has a consensus target price of $41.40, indicating a potential downside of 40.03%. Invacare has a consensus target price of $14.00, indicating a potential upside of 53.85%. Given Invacare's stronger consensus rating and higher probable upside, analysts plainly believe Invacare is more favorable than Establishment Labs.

Earnings & Valuation

This table compares Establishment Labs and Invacare's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million18.06$-38,150,000.00($1.86)-37.11
Invacare$927.96 million0.34$-53,330,000.00($1.06)-8.58

Establishment Labs has higher earnings, but lower revenue than Invacare. Establishment Labs is trading at a lower price-to-earnings ratio than Invacare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Invacare has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are held by institutional investors. Comparatively, 96.7% of Invacare shares are held by institutional investors. 2.6% of Establishment Labs shares are held by insiders. Comparatively, 3.2% of Invacare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Invacare beats Establishment Labs on 10 of the 14 factors compared between the two stocks.


Establishment Labs Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MSA Safety logo
MSA
MSA Safety
2.0$160.99+0.7%$6.29 billion$1.40 billion45.61Analyst Upgrade
Insider Selling
EAR
Eargo
1.0$58.41+4.7%$2.23 billionN/A0.00Earnings Announcement
News Coverage
Avanos Medical logo
AVNS
Avanos Medical
1.3$45.98+0.2%$2.20 billion$697.60 million158.55
Inogen logo
INGN
Inogen
1.4$52.49+0.5%$1.16 billion$361.94 million-583.16Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
News Coverage
Sientra logo
SIEN
Sientra
1.2$7.78+1.2%$392.53 million$83.70 million-4.37
Invacare logo
IVC
Invacare
1.6$9.10+2.1%$313.20 million$927.96 million-7.40
Lakeland Industries logo
LAKE
Lakeland Industries
1.4$31.39+1.8%$251.75 million$107.81 million8.92
SMTI
Sanara MedTech
0.8$31.79+0.3%$200.09 million$11.77 million-24.64
SRGA
Surgalign
1.8$2.44+1.2%$199.29 million$308.38 million-1.36Gap Down
SRGA
Surgalign
1.4$2.44+1.2%$199.29 million$308.38 million-1.36Gap Down
Conformis logo
CFMS
Conformis
1.3$1.01+3.0%$96.50 million$77.43 million-2.97Upcoming Earnings
Gap Up
CLGN
CollPlant Biotechnologies
1.1$14.40+8.1%$81.65 million$2.32 million-7.20Analyst Upgrade
Gap Up
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.0$2.65+1.9%$65.61 million$4.87 million-2.10Gap Down
POAI
Predictive Oncology
1.3$1.47+0.0%$47.38 million$1.41 million-0.23
AHPI
Allied Healthcare Products
0.5$5.00+3.8%$20.05 million$31.89 million0.00
NAOV
NanoVibronix
0.5$1.09+8.3%$11.52 million$530,000.00-1.82
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.